1
|
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Diez-Campelo M, Blanco M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz G, Florensa L. Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30351-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
2
|
Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. Eur J Cancer Care (Engl) 2016; 26. [PMID: 26729645 DOI: 10.1111/ecc.12426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/11/2015] [Indexed: 12/01/2022]
Abstract
The aim of this study was to analyse the eventual changes in health-related quality of life (HRQoL) and left ventricular function (LVF) over a 1-year follow-up period in a cohort of patients with lower risk myelodysplastic syndromes (MDS) receiving standard supportive treatment, in order to identify potential clues for early clinical intervention, as well as to analyse how they relate to haemoglobin levels and other aspects of the disease. A total of 39 adult anaemic patients with lower risk MDS were included in a prospective, observational, multi-centre study. Changes in performance status, functional capacity and HRQoL were collected by using standardised measures (ECOG scale; SPPB, Short Physical Performance Battery; SF-36, Short-Form 36 questionnaire; QLQ-C30, Quality of Life Core Questionnaire; FACT-An, Functional Assessment of Cancer Therapy-Anaemia scale questionnaires respectively). Need for transfusion (Linear Analogue Scale Assessment), as perceived independently by the patient and the haematologist, was also recorded. No changes in HRQoL (or LVF) were found, except for slight reductions in SF-36 physical function (P = 0.034), SPPB gait speed (P = 0.038) and FACT-An score (P = 0.029), all without apparent immediate clinical relevance for HRQoL, that were unrelated to changes in haemoglobin level. Periodical evaluation of gait speed may assist the clinician in early detection of patient's occult functional decline before it becomes clinically relevant.
Collapse
Affiliation(s)
- F Ramos
- Department of Hematology, Hospital Universitario de León and Institute of Biomedicine (IBIOMED), University of Leon, León, Spain
| | - C Pedro
- Department of Hematology, Hospital del Mar, Barcelona, Spain
| | - M Tormo
- Department of Hematology and Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - R de Paz
- Department of Hematology, Hospital Universitario La Paz, Madrid, Spain
| | - P Font
- Department of Hematology, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - E Luño
- Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M Caballero
- Department of Hematology, Hospital Insular, Las Palmas de Gran Canaria, Spain
| | - F Solano
- Department of Hematology, Hospital Nuestra Señora del Prado, Madrid, Spain
| | - M Almagro
- Department of Hematology, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - B Xicoy
- Department of Hematology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | | |
Collapse
|
3
|
Campelo MD, Lorenzo J, Itzykson R, Rojas S, Berthon C, Luño E, Beyne-Rauzy O, Pérez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz J, Gyan E, Such E, Visanica S, Benlloch L, de Botton S, Hernández-Rivas J, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Sanz G, Cañizo M, Fenaux P. 213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30214-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Campelo MD, Lorenzo J, Benlloch L, Lopez-Pavia M, Such E, Bernal T, Luño E, Davila J, Ramos F, Calabuig M, Pomares H, Gonzalez B, Merchan B, Barranco E, Tello RS, Callejas M, Requena M, Jimenez M, Pedreño M, Vicente A, Medina A, Campeny A, Sansa MC, Pedro C, Falantes J, Arilla M, Barez A, Garcia R, Arcos M, Gomez V, Muñoz C, Cervero C, Casaño J, de Paz R, Amigo L, Insunza A, Muñoz J, Cedena M, Gomez M, Font P, del Campo R, Lago CF, Hurtado JG, Latorre ML, Casado AM, Vahi M, Sanz G, Cañizo M. 211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30212-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Calvo X, Arenillas L, Tormo M, Valcárcel D, Luño E, Alonso E, Díez-Campelo M, Ramos F, Pedro C, Arrizabalaga B, Bailen A, Raya J, Ardanaz M, Sanz G, Florensa L. 261 ERYTHROLEUKEMIA APPEARS TO BE A CONTINUUM OF MDS WITH ERYTHROID HYPERPLASIA AND SHARES OUTCOME AND CYTOGENETIC FEATURES WITH RAEB-1 WITH ≥50% ERYTHROPOIESIS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30262-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013; 27:1988-95. [PMID: 23787396 DOI: 10.1038/leu.2013.187] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 05/30/2013] [Accepted: 06/04/2013] [Indexed: 11/09/2022]
Abstract
Monosomal karyotype (MK) is associated with an adverse prognosis in patients in acute myeloid leukemia (AML). This study analyzes the prognostic impact of MK in a cohort of primary, untreated patients with myelodysplastic syndromes (MDS). A total of 431 patients were extracted from an international database. To analyze whether MK is an independent prognostic marker in MDS, cytogenetic and clinical data were explored in uni- and multivariate models regarding overall survival (OS) as well as AML-free survival. In all, 204/431 (47.3%) patients with MK were identified. Regarding OS, MK was prognostically significant in patients with ≤ 4 abnormalities only. In highly complex karyotypes (≥ 5 abnormalities), MK did not separate prognostic subgroups (median OS 4.9 months in MK+ vs 5.6 months in patients without MK, P=0.832). Based on the number of abnormalities, MK-positive karyotypes (MK+) split into different prognostic subgroups (MK+ and 2 abnormalities: OS 13.4 months, MK+ and 3 abnormalities: 8.0 months, MK+ and 4 abnormalities: 7.9 months and MK+ and ≥ 5 abnormalities: 4.9 months; P<0.01). In multivariate analyses, MK was not an independent prognostic factor. Our data support the hypothesis that a high number of complex abnormalities, associated with an instable clone, define the subgroup with the worst prognosis in MDS, independent of MK.
Collapse
Affiliation(s)
- J Schanz
- Department of Hematology and Oncology, University of Göttingen, Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Saumell S, Solé F, Arenillas L, Montoro J, Valcárcel D, Pedro C, Sanzo C, Luño E, Giménez T, Arnan M, Pomares H, De Paz R, Arrizabalaga B, Jerez A, Martínez A, Sánchez-Castro J, Rodríguez J, Raya J, Ríos E, Rodríguez M, Espinet B, Lourdes F. P-068 Trisomy 8 in de novo MDS, constitutional or not constitutional? Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70117-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S. Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27:1826-31. [DOI: 10.1038/leu.2013.120] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Accepted: 04/10/2013] [Indexed: 01/05/2023]
|
9
|
Cordoba I, Gonzalez-Porras J, Such E, Nomdedeu B, Luño E, de Paz R, Carbonell F, Vallespi T, Ardanaz M, Ramos F, Marco V, Bonanad S, Sanchez-Barba M, Costa D, Bernal T, Sanz G, Cañizo M. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res 2012; 36:287-92. [DOI: 10.1016/j.leukres.2011.10.025] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2011] [Revised: 09/21/2011] [Accepted: 10/27/2011] [Indexed: 11/29/2022]
|
10
|
Sanchez-Garcia J, Del Cañizo C, Such E, Nomdedeu B, Luño E, De Paz R, Xicoy B, Valcarcel D, Sierra A, Marco V, Garcia M, Osorio S, Tormo M, Bailen A, Cervero C, Torres-Gomez A, Ramos F, Diez-Campelo M, Belkaid M, Arrizabalaga B, Azaceta G, Bargay J, Arilla M, Caballero M, Falantes J, Sanz G. 64 A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70066-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 2011; 27:951-60. [PMID: 21381892 DOI: 10.1185/03007995.2011.561834] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Current guidelines support the use of erythropoiesis-stimulating agents for the treatment of anemia associated with low-risk myelodysplastic syndromes (MDS). DESIGN AND METHODS Single-arm, open-label, multi-center, phase 2 trial that evaluated the efficacy and safety of darbepoetin alfa (DA) in patients with low or intermediate-risk MDS, hemoglobin <100 g/L, erythropoietin (EPO) levels <500 IU/L and transfusion requirements <2 units/month over the preceding 2 months. Erythroid response (major [MaR] or minor [MiR]) and fatigue (Functional Assessment of Cancer Therapy-Fatigue [FACT-F]) were evaluated at 8, 16 and 24 weeks. DA was initiated at 300 μg weekly. For patients who did not achieve MaR by 8 weeks, filgrastim 300 μg weekly was added. CLINICAL TRIAL REGISTRATION clinicaltrials.gov identifier: NCT01039350. RESULTS Forty-four patients (72.7% transfusion independent) were included. Median age was 76.0 years (range 41.3-92.4), 54.5% were male, and 90.9% presented ECOG Status (0-1). Eighteen patients received filgrastim. An erythroid response was achieved by 31 of 44 patients (70.5%) at week 8 (47.7% MaR, 22.7% MiR), 31 of 44 patients (70.5%) at week 16 (61.4% MaR, 9.1% MiR), and 32 of 44 patients (72.7%) at week 24 (61.3% MaR, 11.4% MiR). Mean (95% CI) change in FACT-F at week 24 was 3.61 (0.72 to 6.51). Baseline EPO levels <100 IU/L were a predictive factor of response. DA was well tolerated. Four mild (two iron deficiencies, flu syndrome and headache) and one fatal (thromboembolic event) adverse events were considered related to darbepoetin alfa. CONCLUSIONS A fixed dose of 300 μg of darbepoetin alfa weekly (with or without filgrastim) seems to be an effective and safe treatment for anemic patients with low or intermediate-risk MDS, low transfusion burden and EPO levels <500 IU/L. Results may not be extrapolable to unselected MDS patients.
Collapse
Affiliation(s)
- A Villegas
- Hematology Department, Hospital Clínico San Carlos Universidad Complutense, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Gonzalez-Porras J, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Luño E, Ardanaz M, Ramos F, Pedro C, Gomez V, de Paz R, Andreu R, Marco V, Tormo M, Bonanad S, de la Serna J, Muñoz J, Benlloch L, Costa D, Bueno J, Bernal T, Sanz G, del Cañizo C. 297 Prognostic impact of severe thrombocytopenia in low risk myelodysplastic syndrome. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70299-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Mallo M, Cervera J, Schanz J, Espinet B, Duch E, Luño E, Steidl C, Martín M, Germing U, Grau J, Pfeilstoecker M, Hernández-Rivas J, Noesslinger T, Calasanz M, Collado R, Fonatsch C, Bureo E, Lübbert M, Ríos R, Stauder R, Arranz E, Hildebrandt B, Slovak M, Cigudosa J, Krieger O, Pedro C, Salido M, Arenillas L, Sanz G, Sanz M, Valencia A, Florensa L, Novell L, del Cañizo C, García-Manero G, Vallespí T, Ohyashiki K, Benlloch L, Haase D, Solé F. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70043-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Such E, Cervera J, Costa D, Solé F, Luño E, Nomdedeu B, Vallespí T, Carbonell F, Ardanaz M, Ramos F, Tormo M, del Cañizo C, Mallo M, Xicoy B, Gomez V, Marco V, Bonanad S, Collado R, Calasanz M, Cruz-Cigudosa J, Hernández-Rivas J, Senent M, Pedro C, Bernal T, Bueno J, Sanz G. P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70109-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Hernández JM, Martín G, Gutiérrez NC, Cervera J, Ferro MT, Calasanz MJ, Martínez-Climent JA, Luño E, Tormo M, Rayón C, Díaz-Mediavilla J, González M, González-San Miguel JD, Pérez-Equiza K, Rivas C, Esteve J, Alvarez MDC, Odriozola J, Ribera JM, Sanz MA. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001; 86:807-13. [PMID: 11522536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
BACKGROUND AND OBJECTIVES To analyze in patients with de novo acute promyelocytic leukemia (APL) treated with an ATRA plus anthracyclin-based protocol if the presence of additional cytogenetic aberrations to the t(15;17) influences: 1. clinical and biological presenting features; 2. disease outcome. DESIGN AND METHODS One hundred and thirteen patients with newly diagnosed APL enrolled in the APL-96 protocol of the Spanish PETHEMA group were studied by conventional karyotyping, FISH and RT-PCR for the PML-RARa fusion. Treatment was homogeneous in all cases and consisted of anthracyclines and ATRA. RESULTS Additional chromosome aberrations were observed in 30% of cases. The most frequent secondary changes were +8 (14 cases), and abnormalities of chromosomes 9 or 3 (4 patients each), and of chromosomes 1 and 8 (3 cases each). No clinical, biological, morphological, immunophenotypic or molecular differences were observed between the group of APLs with t(15;17) alone and the group of patients with additional changes. Patients with additional changes had a higher rates of complete remission (CR) and 4-year disease-free survival (DFS) (97%, and 97%, respectively) than patients with t(15;17) alone (CR, 70% and DFS, 84%) but these differences were not statistically significant. INTERPRETATION AND CONCLUSIONS Patients with APL and additional cytogenetic abnormalities do not show different clinical, biological, morphological or molecular features as compared to patients with t(15;17) alone. The prognosis of patients with APL and t(15;17) alone and those with additional changes is similar in both groups. This study indicates that there is no rationale for administering more intensive treatment in APL patients with additional cytogenetic abnormalities receiving ATRA plus anthracycline-based chemotherapy.
Collapse
Affiliation(s)
- J M Hernández
- Servicio de Hematología, Hospital Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Granada I, Luño E, Ribera JM, Sanzo C, Muñiz SG, Millá F. Translocation (3;10)(q26;q22): a new nonrandom abnormality in three patients with 3q26 involvement. Cancer Genet Cytogenet 2000; 121:99-100. [PMID: 10991622 DOI: 10.1016/s0165-4608(00)00213-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa JC, Diez JL, Bureo E, Marqués ML, Arranz E, Ríos R, Martínez Climent JA, Vallespí T, Florensa L, Woessner S. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol 2000; 108:346-56. [PMID: 10691865 DOI: 10.1046/j.1365-2141.2000.01868.x] [Citation(s) in RCA: 182] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Recently, a consensus International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in the myelodysplastic syndromes (MDS) has been developed. However, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities for which real prognosis at present is uncertain. The main aims of this study were to evaluate in an independent series the prognostic value of the IPSS and to identify chromosomal abnormalities with a previously unrecognized good or poor prognosis in 640 patients. In univariate analyses, cases with single 1q abnormalities experienced poor survival, whereas those with trisomy 8 had a higher risk of acute leukaemic transformation than the remaining patients (P = 0.004 and P = 0.009 respectively). Patients with single del(12p) had a similar survival to patients with a normal karyotype and showed some trend for a better survival than other cases belonging to the IPSS intermediate-risk cytogenetic subgroup (P = 0.045). Multivariate analyses demonstrated that IPSS cytogenetic prognostic subgroup, proportion of bone marrow blasts and haemoglobin level were the main prognostic factors for survival, and the first two characteristics and platelet count were the best predictors of acute leukaemic transformation risk. A large international co-operative study should be carried out to clarify these findings.
Collapse
Affiliation(s)
- F Solé
- Hospital de l'Esperança/Hospital del Mar/Hospital Central l'Aliança (Barcelona), Hospital la Fé (Valencia), Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Gil S, Luño E, Rodriguez JA. Acute myeloblastic leukemia with trilineage myelodysplasia and CD34+ blast cells with abnormal chromatin clumping. Haematologica 1998; 83:750-1. [PMID: 9793262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
Abnormal chromatin clumping can be observed in myelodysplastic syndromes, myeloproliferative syndromes, acute leukemias and the abnormal chromatin clumping syndrome. It occurs mainly in mature and semimature blood cells. We report a case of acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) in which there was chromatin clumping in blast cells.
Collapse
|
19
|
Abstract
We report a case of acute myeloid leukemia (AML) with trisomy 10 as the sole abnormality. We have observed this case among 202 de novo and untreated AML examined cytogenetically in our laboratory during the last 10 years. The patient was an adult man diagnosed with AML-M2. An interesting morphologic finding was the presence in light microscopy and ultrastructural studies of prominent giant "Chediak-Higashi-like" granules in some of the leukemic cells. Cell marker studies showed positivity for CD7 and CD33, as seen in the six previously reported cases. The prognosis has been moderate-good, with a survival of 33 months. Trisomy 10 in AML appears to be a rare recurring numeric chromosomal abnormality and probably linked to a myeloblast subset with a CD33+ and CD7+ phenotype.
Collapse
Affiliation(s)
- E Luño
- Department of Hematology, Hospital Central de Asturias, Oviedo, Spain
| | | | | | | | | |
Collapse
|
20
|
Jonte F, Fernández-Fuertes F, Cecchini C, Luño E, Ordóñez A, Fernández C, Suárez P, Lausín A, Fernández J. [Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia]. Sangre (Barc) 1992; 37:351-4. [PMID: 1293774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
PURPOSE To analyse the survival from diagnosis to blastic crisis, as well as the causes of death and the significance of different features in patients diagnosed of chronic myelogenous leukaemia (CML). MATERIAL AND METHODS The series includes 98 patients who died of CML in Asturias Central Hospital and other nearby hospital between 1970 and 1990. The CML diagnosis had been established according to conventional criteria. The blastic crisis was diagnosed in accordance with morphologic and cytochemical studies, complemented in some cases with the assay of TdT or other markers. The Kaplan-Meier curves and long-rank test were applied to the statistical analysis of survival. The prognostic factors were evaluated by univariate correlation. RESULTS The series' mean age was 48.57 years (range: 6-90) and the M/F ratio was 56/42. Cytogenetic study had been performed in 35 patients, of whom 33 had the Ph' chromosome. Death occurred in the blastic crisis in 67 cases (72%), in the accelerated phase in 14 cases (15%) and in the chronic phase in 12 cases (13%). The cause of death could be determined in 47 cases; of them, 24 (51%) died of infection, 11 (23.4%) of haemorrhage, and the remaining 12 (25.6%) of different complications. The median survival of the group as a whole was 32 months (range: 4-137). For the blastic crisis this figure was reduced to 2.5 months (range: 1-14), the lymphoid forms doing better, 5 months, than the non-lymphoid ones; 1.5 months (p < 0.03). Out of the data evaluated at diagnosis, only haemoglobin and the percentage of blast cells in peripheral blood showed any correlation with survival (r = +0.28, p < 0.05 for haemoglobin, and r = -0.30, p < 0.01 for blast cells). CONCLUSIONS (1) Although most patients die from infection or haemorrhage during the blast crisis, CML increases the risk of death in the accelerated and chronic stages as well. (2) Non-lymphoid blastic crisis has poorer prognosis than the lymphoid form. (3) The concentration of blast cells and haemoglobin in peripheral blood at diagnosis acquire prognostic significance in the present study.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/blood
- Blast Crisis/mortality
- Cause of Death
- Child
- Female
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myeloid, Accelerated Phase/mortality
- Leukemia, Myeloid, Chronic-Phase/mortality
- Life Tables
- Male
- Middle Aged
- Prognosis
- Retrospective Studies
- Spain/epidemiology
- Survival Analysis
Collapse
Affiliation(s)
- F Jonte
- Servicio de Hematología, Hospital Central de Asturias, Oviedo
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Coma A, Jonte F, Zanabili Y, Soto I, Fanjul F, Carrera D, Rayón C, Luño E, Jalón S, Pinto V. [Low-grade non-Hodgkin's lymphomas. Study of 73 cases]. Sangre (Barc) 1992; 37:249-54. [PMID: 1514137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
PURPOSE To analyse the clinico-biologic features at diagnosis and the response to therapy and survival of a group of patients with low-grade non-Hodgkin's lymphoma (NHL). MATERIAL AND METHODS The study comprises 73 NHL patients diagnosed between 1974 and 1989 in the Covadonga Hospital and classified as low-grade in accordance with the international Working Formulation. The first-line treatment regimens used were cyclophosphamide-vincristine-prednisone (CVP), chlorambucil-prednisone (CBL-PRED), radiotherapy, and other combinations. The statistical study was performed by comparative statistics (Student's tests, chi-square), univariate analysis (Cox Mantel method) and multivariate analysis (Cox proportional risks); the BMDP pack was used for the study. RESULTS The median age of the group was 63 years. Stages III and IV were seen at first in 75% of the patients, and 22% of the series had extranodal involvement. CVP was used in 69% of the cases, 7.6 received CBL-PRED, 11% were given radiotherapy, and other combinations were given to 11% of the patients. As a whole, responses were seen in 46 cases (73%), of whom complete remission (CR) was achieved in 49% and partial remission (PR) or minor responses (MR) were attained in 24% of instances. The factors influencing upon CR were: stage (p less than 0.0005), B-symptoms (p 0.004), splenomegaly (p less than 0.801), platelet count and haemoglobin rate (p less than 0.01). The total survival at 10 years was 53%, and the disease-free survival for those attaining CR was 48%, with disease-free median of 81 months. The univariate analysis was influenced in a negative fashion by the following: peripheral blood lymphocyte count below 2 x 10(9)/L, B-symptoms (p less than 0.002), bulky tumoural mass (p less than 0.007), advanced stage (p less than 0.003) and, chiefly, response to treatment (p less than 0.0001). The 10-year survival of the patients achieving CR was 86%, that of both types of response (PR and MR) was 20%, and it was 0% for the failures. CONCLUSIONS 1) Patients in low stages have high possibilities of curation with radiotherapy. 2) CVP for advanced stages provides moderate percentage of response, with CR rate lower than 50%. It is necessary to select those patients with unfavourable prognostic factors in order to use aggressive treatment to achieve CR. 3) Patients attaining CR have better prognosis in spite of the frequent relapses (63% at 10 years).
Collapse
Affiliation(s)
- A Coma
- Servicio de Hematología y Hemoterapia, Hospital Covadonga, Oviedo, Asturias
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Triviño A, Babío J, Pérez P, Luño E. [Leiomyosarcoma of the foot]. Med Clin (Barc) 1992; 98:517. [PMID: 1583954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
23
|
|